Showing results (1-10 of 15) with videos related to
Sort By:
Pageof 2
Journal of Medicinal Chemistry|January 2, 2025
Targeting QPCTL: An Emerging Therapeutic OpportunityLei Yu, Yaoliang Sun, Longyan Xie, et al.European Journal of Medicinal Chemistry|April 12, 2021
Discovery of a potent, selective, and covalent ZAP-70 kinase inhibitorDanni Rao, Heng Li, Xuelian Ren, et al.European Journal of Medicinal Chemistry|April 16, 2023
Discovery of 7H-Pyrrolo[2,3-d]pyrimidine Derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitorsFeifei Wu, Huiyu Li, Qi An, et al.Journal of Medicinal Chemistry|November 17, 2025
Furo[2,3-<i>f</i>]quinazolin-7(6<i>H</i>)-one Derivatives as Potent, Selective, and Orally Bioavailable MAT2A Inhibitors for MTAP-Deficient Cancer TherapyZihan Shi, Kexin Lin, Lijie Lin, et al.Journal of Medicinal Chemistry|December 28, 2024
Discovery of an Efficacious RET PROTAC Degrader with Enhanced Antiproliferative Activity against Resistant Cancer Cells Harboring RET Solvent-Front MutationsQian Zhang, Yingqi He, Danni Rao, et al.Journal of Medicinal Chemistry|September 25, 2025
Proteome-Wide Ligand and Target Discovery by Using Covalent Probes and Natural ProductsJingqing Liu, Chaoming Huang, Shengrong Li, et al.European Journal of Medicinal Chemistry|February 20, 2025
Discovery of a first-in-class PROTAC degrader of histone lysine demethylase KDM4Danni Rao, Yiting Wang, Xiaolong Yang, et al.Bioorganic Chemistry|December 30, 2023
Discovery of a potent and selective covalent threonine tyrosine kinase (TTK) inhibitorYaoliang Sun, Zhiwen Chen, Guobin Liu, et al.Bioorganic & Medicinal Chemistry|June 10, 2025
Design, synthesis and structure-activity relationship studies of novel macrocyclic 2,4-diaminopyrimidines as HPK1 inhibitorsFeifei Wu, Jiaqi Sun, Mingyang Xu, et al.Cell Chemical Biology|January 9, 2024
Discovery of a PROTAC degrader for METTL3-METTL14 complexWenhao Du, Yuting Huang, Xiaoai Chen, et al.Pageof 2